Introduction
============

COPD is a highly prevalent respiratory disease characterized by nonreversible airway obstruction and an increased inflammatory response of the airways. It is predicted that COPD will be the third leading cause of death worldwide by 2020, which will continue to pose an ever-increasing problem well into the future due to high rates of smoking and air pollution.[@b1-copd-12-3511] Meanwhile, COPD is a heterogeneous disease that can be described by different clinical phenotypes through clinical manifestations, physiological indexes, metabolites, inflammatory biomarkers and imaging features.[@b2-copd-12-3511] Diversity of pathological changes of COPD may be associated with different clinical features and metabolites, including responsiveness to bronchodilators or inhaled corticosteroids. Therefore, assessment and management of clinical phenotypes are required to better guide the therapy for patients with COPD rather than focusing on the severity of airflow limitation only.

With the development of computed tomography (CT) imaging technology, high-resolution CT (HRCT) enables direct radiographic assessment of luminal caliber and wall thickness of small airways. According to the dominancy of emphysema with apparent low attenuation areas (LAAs) and the presence of bronchial wall thickening, HRCT phenotypes of COPD were classified into three -- phenotype A: no or mild emphysema with or without bronchial wall thickening; phenotype E: apparent emphysema without bronchial wall thickening and phenotype M: apparent emphysema with bronchial wall thickening.[@b3-copd-12-3511] Recent studies found that COPD phenotypes were different in response to bronchodilator and inhaled glucocorticoid therapy.[@b4-copd-12-3511] Some patients respond well to glucocorticoid treatment, and some patients are less effective. So, HRCT provided detailed anatomic information and morphological changes for identifying phenotypes that can accurately assess the severity and pathology of COPD and evaluated therapeutic schedule and prognosis that allow for determining the best therapy so as to realize better clinical results.

Metabolomics is the comprehensive assessment of endogenous metabolites and can systematically identify and quantify the dynamic multiparametric metabolic response from living systems in a global and targeted manner.[@b5-copd-12-3511] By means of measuring metabolic changes, including carbohydrates, amino acids, peptides, vitamins, nucleic acids, organic acids, alkaloids, inorganic species and polyphenols, in a cell, tissue or organism, biochemical effects induced by a disease or its therapeutic intervention can be determined.^6\ 1^H nuclear magnetic resonance spectroscopy (^1^H-NMR), a data-rich analytical technique, has the potential to generate a highly informative metabolic fingerprint via single measurement, which is possible to associate two or more biomarkers to enhance classification power for more accurate diagnosis and prognosis evaluation, reflecting the biochemical pathway mechanisms of disease.

Until recently, few studies have been carried out to validate the outcome of bronchodilator and corticosteroid treatment of different HRCT phenotypes of COPD and test the qualitative and quantitative metabolic changes pre and post treatment and metabolic characteristics of different HRCT phenotypes. Metabolic profiling of blood provides a global view of the metabolic status by constant regulatory mechanisms. Thus, our study was an attempt to explore the outcome of budesonide--formoterol (inhalation powder) in the treatment of different HRCT phenotypes and investigate the plasma metabolic differences in patients with phenotype E or M before and after treatment, to provide a novel comprehensive description of morphological phenotype to guide personalized therapy.

Patients and methods
====================

Patients
--------

COPD was diagnosed based on clinical history and symptoms and pulmonary function characterized by irreversible airflow limitation according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD).[@b7-copd-12-3511] A total of 163 stable COPD patients (≥40 years old) with post-bronchodilator forced expiratory volume in 1 second (FEV~1~) 40%--80% predicted and FEV~1~/forced vital capacity (FVC) \<70% (moderate-to-severe COPD) were evaluated from outpatient clinics of Respiratory Medicine in the First Affiliated Hospital of Kunming Medical University between December 2015 and June 2017, and 50 patients were ultimately included in a cross-sectional study. The other 113 patients were excluded in line with exclusion criteria, including a respiratory tract infection or exacerbation of an airway disease in the previous 3 weeks, associated respiratory diseases, serious cardiovascular disease, cancer, cognitive impairment, immunodeficiency and unable to complete the protocol. Written informed consent was obtained from each subject, and the protocol was approved by the ethics committee of Kunming Medical University.

Study design
------------

Phenotype A is characterized by the absence of emphysema or little emphysema showing LAA ≤ grade 1 regardless of existing bronchial wall thickening. We cannot exclude that patients with phenotype A may be asthmatic with fixed airflow limitation since airway remodeling, or bronchitis with irreversible airflow limitation. Therefore, phenotype A was not incorporated into the study. COPD patients were assigned into phenotype E pretreatment (EQ, n=22), phenotype M pretreatment (MQ, n=28), phenotype E posttreatment (EH, n=22) and phenotype M posttreatment (MH, n=28) based on the HRCT findings and pre--posttreatment. Budesonide--formoterol-pressurized metered-dose inhaler (160/4.5 µg ×2 inhalations; 320/9 µg), twice daily, was prescribed for COPD patients in a 3-month treatment period.[@b8-copd-12-3511] The following data collected at inclusion were compared between groups: medical and smoking history, physical examination, blood samples and lung function including post-bronchodilator ratio of FEV~1~ to FVC~%~ (FEV~1~/FVC~%~) and FEV~1~ in percentage of predicted (FEV~1%~), St George's Respiratory Questionnaire (SGRQ) score and chest HRCT.

HRCT phenotypes and evaluation of emphysema and bronchitis
----------------------------------------------------------

HRCT scanning (SomAToM; Siemens, Munich, Germany) at full inspiration (at tumor-to-liver contrast \[TLC\] level with 140 kVp, 200 mA and pitch of 1.375) was used. Three slices, 1 mm thick, were obtained at three anatomical levels: upper (near the superior margin of the aortic arch), middle (at the level of the carina) and lower lung field level (at the level of the orifice of the inferior pulmonary veins). Emphysema was scored visually by LAA in the bilateral upper, middle and lower lung fields on the basis of the method by Goddard et al.[@b9-copd-12-3511] The score in each dimension was calculated according to the ratio of LAA to occupy in the lung field as follows: score 0, LAA \<5%; score 1, 5% ≤ LAA \<25%; score 2, 25% ≤ LAA \<50%; score 3, 50% ≤ LAA \<75% and score 4, LAA ≥75%. The severity of emphysema was graded in conformity to the sum of scores taken from six dimensions as follows: grade 0, total score =0; grade 1, total score =1--6; grade 2, total score =7--12; grade 3, total score =13--18 and grade 4, total score =19--24.[@b3-copd-12-3511] Bronchial wall thickening in all lung fields was graded visually as follows: grade 0, bronchial wall thickening \<30% of adjacent pulmonary artery diameter, and grade 2, bronchial wall thickening ≥50% of adjacent pulmonary artery diameter.[@b3-copd-12-3511] The patients were classified into the two phenotypes according to the visual HRCT findings as follows: phenotype E (severity of emphysema ≥ grade 2 without bronchial wall thickening) and phenotype M (severity of emphysema ≥ grade 2 and bronchial wall thickening ≥ grade 1).

Sample preparation and ^1^H-NMR measurements
--------------------------------------------

Blood samples (9 mL each) were collected in the morning and centrifuged at 4,000 rpm for 10 minutes at 4°C. The plasma samples were then immediately frozen and stored at −80°C until metabolomic analysis. For NMR analysis, plasma aliquots were thawed at room temperature, and then the plasma (400 µL) was mixed with phosphate-buffered saline (PBS; 0.6 M, 30 µL) and D~2~O (170 µL). The homogenized mixture was subsequently centrifuged at 12,000 rpm for 10 minutes at 4°C. After centrifugation, the supernatant (500 µL) for each sample was transferred into a 5 mm NMR tube.

^1^H-NMR measurements were obtained on a Varian INOVA 600 spectrometer at a 1H frequency of 600.13 MHz. Using a solvent pre-saturation pulse sequence, ^1^H-NMR spectra of the samples to suppress the residual water resonance were acquired. Using a Carr--Purcell--Meiboom--Gill pulse sequence, ^1^H-NMR spectra of the samples were acquired. At 128,000 data points, free induction decays (FIDs) were collected with a spectral width of 8,000 Hz and 32,000 sampling points. The cumulative number of 64 times and acquisition time of 2.04 seconds provided a total pulse recycle delay of 2.00 seconds. The data were zero filled by a factor, and FIDs were multiplied by an exponential weighting function equivalent to a line broadening of 0.5 Hz before the Fourier transform.

Data processing and multivariate statistical analysis
-----------------------------------------------------

The phase and baseline of all ^1^H-NMR spectra were manually corrected using Mest Re Nova software (version 9.0.1.13254; Mestrelab Research, Santiago de Compostela, Spain). The range of δ 10--0 ppm in standard ^1^H-NMR spectra was automatically segmented into 400 regions at 0.01 ppm intervals with δ 4.4--0.4 ppm. The data from each sample were normalized to total area to correct for the NMR response shift. The spectrum was divided into a specified number of regions and the total signal area was integrated within each region to provide a numerical value. These values were then used as variables for data analysis.

The reduced and normalized NMR spectral data were submitted to SIMCA-Package (SIMCA-P) version 11.0 (Umetrics, Umea, Sweden) software package for multivariate analysis. The unsupervised principal component analysis (PCA) was first carried out to detect intrinsic clusters and possible outliers within the data set using mean-centered data. Subsequently, supervised partial least squares discriminant analysis (PLS-DA) modeling was applied to improve class discrimination. SIMCA-P was used to generate all the PLS-DA models and score plots and was performed to clarify which chemical shift regions carry the separating information. Cross-validation was used to validate the PLS-DA model according to the default settings in the software. The obtained parameters R^2^X (represents the total explained variation of the model) and Q^2^ (represents the predictability of the model) were further used to confirm the validity of these models. The significantly different expression of compound peaks (variable importance \[VIP\] \>1.0) was listed by the software. Subsequently, the differentiated expressions of peaks were analyzed by discriminatory analysis.

Statistical analysis
--------------------

SPSS 20.0 software (IBM Corporation, Armonk, NY, USA) was used for statistical analysis of the clinical data. Student's *t*-test was used to compare two group experiments, and paired *t*-test was used to compare before and after treatment group experiments. *χ*^2^ test was used to compare categorical variables. Data are expressed as mean ± SD. *P*\<0.05 was considered statistically significant.

Metabolite set enrichment analysis (MSEA)
-----------------------------------------

A set of significantly altered metabolites was used as the input for the MSEA to identify the most altered metabolic pathways. The MSEA was performed with web portal for pathway analysis and visualization (<http://www.msea.ca/MSEA/faces/Home.jsp>). Overrepresentation analysis was used to screen affected pathways.

Results
=======

Baseline characteristics of study participants
----------------------------------------------

The characteristics of the 50 COPD patients enrolled in the study are summarized in [Table 1](#t1-copd-12-3511){ref-type="table"}. There was no significant difference between phenotype E and phenotype M with respect to age, gender, BMI and smoking (*P*\>0.05). Regarding lung function data, FEV~1%~ predicted and FEV~1~/FVC~%~ of both phenotype E and phenotype M were significantly higher in posttreatment compared with the pretreatment following 3 months (*P*\<0.05). FEV~1%~ predicted and FEV~1~/FVC~%~ had no significant difference between phenotype E and phenotype M in pretreatment (*P*\>0.05). FEV~1%~ predicted and FEV~1~/FVC~%~ of phenotype M were significantly higher in posttreatment compared with phenotype E (*P*\<0.05), and the change in FEV~1%~ predicted and FEV~1~/FVC~%~ of phenotype M in pre--posttreatment was also significantly higher (*P*\<0.05). SGRQ total score of both and phenotypes E and M was improved significantly in posttreatment compared with pretreatment (*P*\<0.05). SGRQ total score of phenotype M in pretreatment and posttreatment was significantly higher compared with phenotype E (*P*\<0.05), and the change in SGRQ total score of phenotype M in pre--posttreatment was significantly higher (*P*\<0.05).

Determination of metabolic differences in plasma according to ^1^H-NMR spectroscopy
-----------------------------------------------------------------------------------

With the major metabolites in the integrate regions assigned, typical ^1^H-NMR spectra of COPD patient samples are shown in [Figure 1](#f1-copd-12-3511){ref-type="fig"}. The spectra were processed and converted into 400 integral regions of 0.01 ppm width. The metabolic-related ^1^H-NMR chemical shift spectrum can be found in the published literatures and online databases (<http://www.hmdb.ca>).[@b10-copd-12-3511] Abundant endogenous metabolites including several amino acids were detected according to these spectral data. It is impossible to get consistent comparison results across all the subjects because of the high individual variability and large complexity, and the NMR spectra of samples were subjected to multivariate statistical data analysis to identify the metabolic differences.

Identification of discriminatory metabolites
--------------------------------------------

PCA was first performed based on the normalized NMR spectral data as an exploratory unsupervised analysis to obtain a general overview of sample distribution. The first and second principal components (PC1 and PC2) were calculated for the models. The PCA score plot is shown in [Figure 2](#f2-copd-12-3511){ref-type="fig"}, and the explained variances are shown in parentheses. Panel validation could be discriminated according to their metabolite content. The two different groups are completely separated.

To corroborate data and reinforce classification, the PLS-DA was applied in our study. The PLS-DA score plot is shown in [Figure 2](#f2-copd-12-3511){ref-type="fig"}. Panel confirms the existence of two clearly distinct groups of individuals. The two different groups are characterized by different metabolite concentrations. The resulting supervised models were tested by iteratively predicting the class membership of every sample. Subsequently, the obtained parameters R^2^X, which represents the total explained variation of the model, and Q^2^, which represents the predictability of the model, were used to describe the quality of these models. The expected R^2^ and Q^2^ depend highly on their application fields and should be \>0.5 and \>0.4, respectively, indicating a significant biological model. In our established model, the value of R^2^ in [Table 2](#t2-copd-12-3511){ref-type="table"} indicates that the PLS-DA model had been successfully established. As summarized in [Table 2](#t2-copd-12-3511){ref-type="table"}, the model has good fit and can well differentiate different groups as follows: MH and MQ (R^2^X =0.029, Q^2^ =0.338); EH and EQ (R^2^X =0.107, Q^2^ =0.273); EQ and MQ (R^2^X =0.203, Q^2^ =0.547); EH and MH (R^2^X =0.102, Q^2^ =0.0473). The VIP score is a quantitative measure that indicates the contribution of a single variable to the description of both independent variables and the response variable. VIP \>1 was considered to be the greatest contributor to the group difference. Finally, independent *t*-test (*P*\<0.05) and fold change (FC ≥2) between two groups were used to screen discriminatory metabolites.

The main molecular markers for the observed differences were found ([Table 3](#t3-copd-12-3511){ref-type="table"}). The metabolomic analysis of the plasma of phenotype E patients showed that adenosine diphosphate (ADP), guanosine, choline, malonate, tyrosine, glycine, proline, [l]{.smallcaps}-alanine, [l]{.smallcaps}-valine and leucine were significantly upregulated, meanwhile pyruvic acid, acetone and lactate were significantly downregulated in posttreatment compared with pretreatment (*P*\<0.05). A total of 13 metabolites were found to be regulated in posttreatment compared with pretreatment of phenotype M patients. ADP, guanosine, [l]{.smallcaps}-threonine, choline, glycine, proline, tyrosine, [l]{.smallcaps}-alanine, [l]{.smallcaps}-valine and leucine were significantly upregulated, and uridine, acetone and lactate were down-regulated (*P*\<0.05). Several biomarkers were identified, of which glycine, [d]{.smallcaps}-glucose and pyruvic acid levels were lower, while succinate and lactate levels were higher in phenotype M compared with phenotype E before treatment (*P*\<0.05). After treatment, glycine, [d]{.smallcaps}-glucose and pyruvic acid levels were still lower, while proline, [l]{.smallcaps}-valine and leucine levels were higher in phenotype M compared with phenotype E (*P*\<0.05).

Discussion
==========

In this study, we have identified the treatment outcome of budesonide--formoterol in patients with phenotype E and M as well as analyzed discriminatory metabolites in patients with phenotype E or M before and after treatment. Furthermore, discriminatory metabolites were determined between patients with phenotypes E and M including pre- and post-treatment. Our analyses showed that baseline characteristics and lung function measurements might not differentiate phenotype E from M. SGRQ total score was associated with the HRCT phenotypes. Inhaled corticosteroid plus bronchodilator therapy for both phenotypes E and M was effective. However, phenotype E and phenotype M were different in response to therapy. Patients with phenotype M in response to therapeutic effects were significantly greater compared with phenotype E. Hence, it may be reasonable that the presence of bronchial wall thickening is significantly associated with the reversibility in response to the treatment with bronchodilator and corticosteroid. Patients with phenotype M also show increased airway inflammation and wall thickening in the small airway which might be implicated in the reversibility by bronchodilator and corticosteroid. In contrast, patients with phenotype E appear mild airway wall thickening in the small airway, and the airflow limitation is mainly by reason of the decreased elastic recoil. Moreover, combined usage of formoterol and budesonide has been demonstrated to underline a greater effect on airway inflammation than either drug alone with a complementary interaction. Therefore, it seems likely that bronchial wall thickening may be an indicator for predicting the better response to the treatment with bronchodilator and corticosteroid.[@b11-copd-12-3511]

Metabolites analyzed by ^1^H-NMR with high-efficiency qualitative and quantitative spectral differences have been demonstrated by several authors to diagnose a variety of respiratory diseases.[@b12-copd-12-3511],[@b13-copd-12-3511] Metabolic profiling of serum and urine by ^1^H-NMR-based spectroscopy had been reported previously to discriminate patients with COPD and healthy individuals.[@b14-copd-12-3511] Metabolomic analysis recently identified the gender dependency of circulating metabolic profiles in COPD, providing further molecular evidence of a female-driven subphenotype of COPD.[@b15-copd-12-3511] Significantly increased or decreased metabolites among these studies were shown to be responsible for intergroup separation. On the basis of these interesting results, the metabolite content of plasma collected from subjects with COPD was explored to find biomarkers, to provide HRCT classification and to respond to therapeutic effect.

The metabolomic analysis of the plasma in patients with phenotypes E and M showed significant differences before and after treatment. We speculate that COPD patients with reduced pulmonary ventilation function make less oxygen accessible to transport from the lungs to other parts of the body. Pulmonary gas exchange impairment may lead to arterial hypoxemia and reduced oxygen delivery to skeletal muscle during exercise. Exercise intolerance and dyspnea are the most frequently occurring complaints in patients. Weakness of both skeletal and respiratory muscles contributes to these complaints, while locomotor muscle wasting is related to altered muscle metabolism and gene expression in COPD patients.[@b16-copd-12-3511],[@b17-copd-12-3511] Then, the body resorts to consuming carbohydrate, protein and fat at a higher rate as a compensatory mechanism. Amino acids are used in the biosynthesis of proteins, and their reduced levels are consistent with muscle wasting. The higher routine respiration in COPD could be controlled by elevated cytoplasmic ATPase activity leading to elevated mitochondrial ADP which can stimulate respiration in the absence of exogenous ADP titration.[@b18-copd-12-3511] A previous study found that muscle energy metabolism of stable COPD patients was disturbed, including an imbalance in production and utilization of (adenosine triphosphate) ATP, and lower ATP/ADP ratio in the patients.[@b19-copd-12-3511] Guanosine can be phosphorylated to become guanosine monophosphate, cyclic guanosine monophosphate, guanosine diphosphate and guanosine triphosphate to play important roles in various biochemical processes such as synthesis of nucleic acids and proteins. Choline can suppress inflammation and oxidative stress when given in substantial amounts in patients with asthma. Increased choline levels may be an adaptive response to control the severity of inflammation.[@b20-copd-12-3511] Malonate is a competitive inhibitor of the enzyme succinate dehydrogenase which can decrease cellular respiration. [l]{.smallcaps}-Valine and leucine belong to branched-chain amino acids (BCAAs), which regulate protein turnover and glucose homeostasis with a continuous flux of BCAAs to skeletal muscle.[@b21-copd-12-3511] Decreased BCAAs have been found in previous studies of COPD patients, and the lower levels of BCAAs are the result of proteolysis, potentially due to wasting and enhanced gluconeogenesis under hypoxia conditions.[@b22-copd-12-3511],[@b23-copd-12-3511] Tyrosine, glycine, proline, [l]{.smallcaps}-threo-nine and [l]{.smallcaps}-alanine are proteinogenic amino acids which can be transformed into glucose for energy. Uridine plays a role in the glycolysis pathway of galactose. Lactate levels are associated with hypoxia-induced restricted exercise capacity. A significant decrease in uridine and lactate after treatment shows that anaerobic glycolysis energy supply is reduced. Pyruvic acid supplies energy through the citric acid cycle when oxygen is present, and alternatively ferments to produce lactate when oxygen is lacking. Pyruvate, the conjugate base, is a key intermediate in several metabolic pathways. Elevated expression level of pyruvate has also been found in serum from lung cancer as well as exhaled breath condensate samples from COPD patients.[@b24-copd-12-3511],[@b25-copd-12-3511] Acetone is produced from acetyl-CoA when energy is obtained from fatty acids due to lack of carbohydrates. The observed increase in acetone suggests the utilization of storage lipids as an alternative energy resource. Persisting airway inflammation, irreversible airflow obstruction and an existing systemic inflammatory response of COPD patients lead to consumption of body energy and malnutrition, which induce disordered energy and lipid and amino acid metabolism. Budesonide--formoterol treatment improves lung function, decreases symptoms, acts anti-inflammatory effects, and metabolic change occured in parallel pattern, indicating metabolites are associated with treatment regulation.

Several biomarkers were identified between phenotypes E and M before treatment. Repeated exposure to noxious particles can trigger a distinct inflammatory cascade in the small airways and lung parenchyma of COPD. Lung inflammatory proteinase production and alveolar septal cell apoptosis lead to destruction of alveolar structures to form emphysema. Chronic inflammation-induced matrix deposition around the small airways causes the small airway wall thickening.[@b26-copd-12-3511] Bronchial wall thickening in large or intermediate airways on HRCT reflects the wall thickening in smaller airways.[@b27-copd-12-3511] Therefore, the higher level of inflammation is likely to generate the thicker airway walls. It can be concluded that phenotype M might show increased levels of inflammation versus phenotype E. Many aspects of the clinical phenotype with COPD are also related to inflammation.[@b28-copd-12-3511] Glycine plays a part in regulating the transcription of inflammatory cytokines in inflammatory cells to suppress the formation of free radicals and inflammatory cytokines.[@b29-copd-12-3511] In addition, glycine consumption and expression of the mitochondrial glycine biosynthetic pathway are strongly correlated with rates of proliferation across cancer cells.[@b30-copd-12-3511] Pyruvic acid is closely related to inflammatory cells, and their factors which can remove excess free radicals inhibit cytokine chemokines and related mRNA expression to act as antioxidant and anti-inflammatory.[@b31-copd-12-3511] The lower levels of glycine and pyruvic acid in phenotype M may suggest its high inflammation level. The decreased level of glucose was related to the proliferation of inflammatory cells which needed carbohydrates to supply energy. Lactate bridges the gap between high lactate levels in wound healing, chronic inflammation and cancer development.[@b32-copd-12-3511] So, phenotype M showed increased lactate level led to bronchial wall thickening. Succinate is an intermediate of the tricarboxylic acid (TCA) cycle and plays a crucial role in ATP in mitochondria. Recent study has found that succinate may directly regulate hypoxia-inducible factor-1α (HIF-1α) signaling to promote inflammation by macrophages, and succinate as an inflammatory signal.[@b33-copd-12-3511] After treatment, there were differences in metabolites between phenotypes M and E. The increased amino acid levels revealed that the effect of the therapy in phenotype M was better than that in phenotype E, when lung function was improved and inflammation was suppressed after treatment. The MSEA indicated that the main differences were related to protein biosynthesis, amino acid metabolism, gluconeogenesis and glycolysis ([Figure 3](#f3-copd-12-3511){ref-type="fig"}).

There are some limitations in the current study. The data were analyzed in a moderately limited number of subjects, and without other samples such as lung tissue, exhaled breath condensate and urine. Moreover, individual's metabolic profile reflects complex interactions among genome, environmental factors, diet and symbiotic gut microbes.[@b34-copd-12-3511] The combinations of different metabolic profiles with gene, genetic transcription and protein are proposed to explore bio-markers involved with COPD. To develop these meaningful biomarkers applied to the clinic need further validation.

Conclusion
==========

Overall, the results suggest that the HRCT morphological phenotypes of COPD show several clinical characteristics and different responses to treatment with budesonide--formoterol. Bronchial wall thickening may be an indicator for predicting the better response to the treatment with bronchodilator and corticosteroid. This study focuses on the discovery of potential biomarkers of different aspects of COPD. Metabolic profiling exhibits a significantly metabolic discrimination between phenotype E pretreatment and posttreatment, phenotype M pretreatment and posttreatment, phenotype E pretreatment and phenotype M pretreatment and phenotype E posttreatment and phenotype M posttreatment. Certain metabolites are identified that are closely related to treatment and phenotype. Metabolic change in phenotype E or phenotype M after treatment may be involved with energy, amino acids and lipid metabolism disturbance regulated by lung function improvement, symptom reduction and anti-inflammatory effects. Metabolic difference between phenotypes E and M including pretreatment and posttreatment may be associated with inflammatory proliferation and inflammation suppression. This study shows that metabolic profiling of human plasma samples could become a promising clinical tool to differentiate HRCT phenotypes of COPD and therapeutic assessment.
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![(**A**) The spectrum shows a wide range of metabolites. Representative ^1^H-NMR spectrum of plasma samples obtained from (**B**) phenotype E pretreatment, (**C**) phenotype E posttreatment, (**D**) phenotype M pretreatment and (**E**) phenotype M posttreatment.\
**Abbreviation:** ^1^H-NMR, ^1^H nuclear magnetic resonance spectroscopy.](copd-12-3511Fig1){#f1-copd-12-3511}

![PCA (**A**--**D**) and PLS-DA (**E**--**H**) score plots demonstrated good separation between different groups.\
**Note:** Ellipses display 95% confidence regions.\
**Abbreviations:** EH, phenotype E posttreatment; EQ, phenotype E pretreatment; MH, phenotype M posttreatment; MQ, phenotype M pretreatment; PCA, principal component analysis; PLS-DA, partial least squares discriminant analysis.](copd-12-3511Fig2){#f2-copd-12-3511}

![Results of the MSEA for COPD patients.\
**Notes:** The horizontal bar graph shows the most affected metabolic pathways. The most significant differences include protein biosynthesis, amino acid metabolism, gluconeogenesis and glycolysis.\
**Abbreviation:** MSEA, metabolite set enrichment analysis.](copd-12-3511Fig3){#f3-copd-12-3511}

###### 

Demographics and clinical characteristics of COPD patients in the two phenotypes

  Variables                                           Phenotype E (n=22)                                        Phenotype M (n=28)                                                                                     *P*-value
  --------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -----------
  Gender, male                                        20 (90.91%)                                               25 (89.29%)                                                                                            0.849
  Age, years                                          73.64±6.31                                                70.18±8.51                                                                                             0.118
  BMI (kg/m^2^)                                       21.21±2.25                                                19.65±3.39                                                                                             0.069
  Current smoker                                      6 (27.27%)                                                8 (28.57%)                                                                                             0.919
  Smoking, pack/year                                  43.82±24.35                                               44.28±26.03                                                                                            0.949
  FEV^1^/FVC~%~ in pretreatment                       48.53±9.35                                                50.92±11.26                                                                                            0.427
  FEV^1^/FVC~%~ in posttreatment                      63.62±13.94[a](#tfn2-copd-12-3511){ref-type="table-fn"}   74.43±14.73[a](#tfn2-copd-12-3511){ref-type="table-fn"},[b](#tfn3-copd-12-3511){ref-type="table-fn"}   0.011
  Change in FEV^1^/FVC~%~ in pre--posttreatment       14.93±3.24                                                25.56±4.12[b](#tfn3-copd-12-3511){ref-type="table-fn"}                                                 \<0.001
  FEV~1%~ predicted in pretreatment                   47.46±10.78                                               46.12±14.21                                                                                            0.715
  FEV~1%~ predicted in posttreatment                  62.49±11.32[a](#tfn2-copd-12-3511){ref-type="table-fn"}   73.15±15.22[a](#tfn2-copd-12-3511){ref-type="table-fn"},[b](#tfn3-copd-12-3511){ref-type="table-fn"}   0.009
  Change in FEV~1%~ predicted in pre--posttreatment   15.17±3.55                                                26.40±5.13[b](#tfn3-copd-12-3511){ref-type="table-fn"}                                                 \<0.001
  SGRQ total score in pretreatment                    39.23±7.98                                                58.06±10.42[b](#tfn3-copd-12-3511){ref-type="table-fn"}                                                \<0.001
  SGRQ total score in posttreatment                   30.69±6.59[a](#tfn2-copd-12-3511){ref-type="table-fn"}    38.38±6.51[a](#tfn2-copd-12-3511){ref-type="table-fn"},[b](#tfn3-copd-12-3511){ref-type="table-fn"}    0.001
  Change in SGRQ total score in pre--posttreatment    8.79±2.19                                                 19.65±4.73[b](#tfn3-copd-12-3511){ref-type="table-fn"}                                                 \<0.001

**Notes:** Data are presented as mean ± SD.

*P*\<0.05 compared with pretreatment.

*P*\<0.05 compared with phenotype E. Phenotype E, emphysema without bronchial wall thickening; Phenotype M, emphysema with bronchial wall thickening.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SGRQ, St George's Respiratory Questionnaire.

###### 

Summary of the parameters for assessing the quality of the PLS-DA model

  Model       No    R^2^X   R^2^Y   Q^2^
  ----------- ----- ------- ------- --------
  MH and MQ   100   0.029   0.624   0.338
  EH and EQ   100   0.107   0.920   0.273
  EQ and MQ   100   0.203   0.750   0.547
  EH and MH   100   0.102   0.828   0.0743

**Notes:** No represents the number of principal component obtained by cross-validation; R^2^X, variation explanation in X; R^2^Y, variation explanation in the response to Y; Q^2^, predict variation capability of compound.

**Abbreviations:** EH, phenotype E posttreatment; EQ, phenotype E pretreatment; MH, phenotype M posttreatment; MQ, phenotype M pretreatment; PLS-DA, partial least squares discriminant analysis.

###### 

Quantitative comparison and the relative integrals of metabolites in the EQ, MQ, EH and MH groups

  Compound                    ppm    VIP      EQ (n=22)                                                          MQ (n=28)                                                           EH (n=22)                                                           MH (n=28)
  --------------------------- ------ -------- ------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------
  ADP                         8.28   1.5864   (2.34±1.04) ×10^−4^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (1.74±1.17) ×10^−4^                                                 (5.19±3.73) ×10^−4^                                                 (5.71±2.71) ×10^−4^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Guanosine                   7.98   1.2857   (3.44±1.03) ×10^−4^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (3.28±0.92) ×10^−4^                                                 (3.68±1.45) ×10^−3^                                                 (3.22±1.35) ×10^−3^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Tyrosine                    7.16   1.6328   (1.52±1.13) ×10^−4^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (1.28±1.19) ×10^−4^                                                 (2.62±1.20) ×10^−4^                                                 (2.52±1.26) ×10^−4^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Uridine                     5.88   1.5898   (1.14±0.93) ×10^−2^                                                (1.59±1.19) ×10^−2^                                                 (1.05±0.78) ×10^−2^                                                 (0.95±0.58) ×10^−2^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Maltose                     5.22   1.0970   (1.20±1.24) ×10^−1^                                                (1.45±1.03) ×10^−1^                                                 (1.52±1.41) ×10^−1^                                                 (1.15±0.94) ×10^−1^
  Sucrose                     4.26   1.6069   (2.78±1.10) ×10^−1^                                                (2.35±0.84) ×10^−1^                                                 (3.22±1.15) ×10^−1^                                                 (2.58±0.62) ×10^−1^
  [l]{.smallcaps}-Threonine   4.25   2.1840   (2.73±0.88) ×10^−1^                                                (2.20±0.97) ×10^−1^                                                 (3.21±1.25) ×10^−1^                                                 (2.71±0.77) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  [d]{.smallcaps}-Glucose     3.70   1.5992   6.25±1.39                                                          5.18±0.61[c](#tfn10-copd-12-3511){ref-type="table-fn"}              5.97±1.75[d](#tfn11-copd-12-3511){ref-type="table-fn"}              4.94±0.99
  Glycine                     3.57   2.5918   (7.70±1.58) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (6.14±1.26) ×10^−1^,[c](#tfn10-copd-12-3511){ref-type="table-fn"}   (8.79±1.91) ×10^−1^,[d](#tfn11-copd-12-3511){ref-type="table-fn"}   (7.33±1.70) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Proline                     3.33   1.9525   (1.99±0.54) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (1.61±0.99) ×10^−1^                                                 (4.80±0.77) ×10^−1^,[d](#tfn11-copd-12-3511){ref-type="table-fn"}   (5.34±0.98) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Betaine                     3.24   1.4522   2.12±0.47                                                          1.93±0.28                                                           2.06±0.39                                                           2.02±0.40
  Choline                     3.18   2.2438   (2.62±0.89) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (2.14±0.84) ×10^−1^                                                 (3.38±0.33) ×10^−1^                                                 (2.91±1.59) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Malonate                    3.12   1.6003   (6.36±2.02) ×10^−3^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (7.49±2.19) ×10^−3^                                                 (8.63±2.92) ×10^−3^                                                 (8.06±2.23) ×10^−3^
  [l]{.smallcaps}-Lysine      3.07   1.3124   (3.34±1.74) ×10^−1^                                                (3.07±0.92) ×10^−1^                                                 (3.41±1.25) ×10^−1^                                                 (3.53±1.44) ×10^−1^
  Creatine                    3.05   1.3495   (2.54±0.63) ×10^−1^                                                (1.90±0.28) ×10^−1^                                                 (2.64±0.91) ×10^−1^                                                 (2.02±0.49) ×10^−1^
  Asparagine                  2.86   1.1751   (2.51±1.12) ×10^−2^                                                (2.11±1.78) ×10^−2^                                                 (2.91±1.61) ×10^−2^                                                 (2.69±1.25) ×10^−2^
  Aspartate                   2.82   1.1520   (5.73±1.12) ×10^−2^                                                (5.16±1.53) ×10^−2^                                                 (6.23±1.64) ×10^−2^                                                 (5.91±1.44) ×10^−2^
  Succinate                   2.38   1.3575   (2.08±0.71) ×10^−1^                                                (2.67±0.68) ×10^−1^,[c](#tfn10-copd-12-3511){ref-type="table-fn"}   (1.97±0.50) ×10^−1^                                                 (2.25±0.88) ×10^−1^
  Pyruvic acid                2.35   1.6409   8.77±2.76[a](#tfn8-copd-12-3511){ref-type="table-fn"}              1.29±0.31[c](#tfn10-copd-12-3511){ref-type="table-fn"}              7.37±1.37[d](#tfn11-copd-12-3511){ref-type="table-fn"}              1.34±0.42
  Acetone                     2.22   1.5726   (5.20±2.06) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (4.89±0.79) ×10^−1^                                                 (4.07±1.48) ×10^−1^                                                 (3.79±0.57) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Ornithine                   1.82   1.6560   (9.44±2.30) ×10^−3^                                                (8.49±2.70) ×10^−3^                                                 (7.99±2.76) ×10^−3^                                                 (7.51±2.40) ×10^−3^
  [l]{.smallcaps}-Alanine     1.46   1.0100   (1.38±0.75) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (1.03±0.34) ×10^−1^                                                 (2.24±1.10) ×10^−1^                                                 (1.94±0.38) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Lactate                     1.30   1.0361   9.76±4.29[a](#tfn8-copd-12-3511){ref-type="table-fn"}              12.58±4.60[c](#tfn10-copd-12-3511){ref-type="table-fn"}             7.29±2.57                                                           6.38±2.82[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Isopropyl alcohol           1.16   2.4802   1.67±0.43                                                          1.39±0.68                                                           1.42±0.42                                                           1.18±0.51
  [l]{.smallcaps}-Valine      1.01   1.4451   (2.27±0.94) ×10^−1^,[a](#tfn8-copd-12-3511){ref-type="table-fn"}   (2.02±0.93) ×10^−1^                                                 (3.42±0.93) ×10^−1^,[d](#tfn11-copd-12-3511){ref-type="table-fn"}   (3.91±0.79) ×10^−1^,[b](#tfn9-copd-12-3511){ref-type="table-fn"}
  Leucine                     0.94   1.5185   1.04±0.12[a](#tfn8-copd-12-3511){ref-type="table-fn"}              (9.78±1.55) ×10^−1^                                                 1.15±0.18[d](#tfn11-copd-12-3511){ref-type="table-fn"}              1.25±0.13[b](#tfn9-copd-12-3511){ref-type="table-fn"}

**Notes:** A total of 26 characteristic resonances were observed in plasma of the four groups (VIP value \>1.0).

*P*\<0.05 compared with EH.

*P*\<0.05 compared with MH.

*P*\<0.05 compared with MQ;

*P*\<0.05 compared with MH. ppm, chemical shift.

**Abbreviations:** ADP, adenosine diphosphate; EQ, phenotype E pretreatment; MQ, phenotype M pretreatment; EH, phenotype E posttreatment; MH, phenotype M posttreatment; VIP, variable importance.
